Acetylation of proteins as novel target for antitumor therapy: review article

Area of Science:

• Molecular Biology
• Biochemistry
• Cancer Research

Background:

• Histone acetylation regulates gene expression, impacting cell proliferation, differentiation, and apoptosis.
• Aberrant activity of histone acetyltransferases (HATs) and histone deacetylases (HDACs) is implicated in various cancers.
• HDACs and HATs also modify non-histone proteins, affecting diverse cellular processes.

Purpose of the Study:

• To explore the anticancer potential of HDAC inhibitors.
• To investigate the mechanisms underlying HDAC inhibitor-induced cancer cell apoptosis and growth arrest.
• To address the challenge of understanding the molecular basis for tumor selectivity of HDAC inhibitors.

Main Methods:

• Review of existing literature on HDAC inhibitors and their mechanisms of action.
• Analysis of clinical studies involving HDAC inhibitors.
• Exploration of the role of histone acetylation and non-histone protein targets.

Main Results:

• HDAC inhibitors demonstrate efficacy in inducing growth arrest and apoptosis in diverse human cancer cells.
• The observed anti-cancer effects cannot be solely explained by changes in histone acetylation.
• Ongoing clinical trials are evaluating the therapeutic potential of these agents.

Conclusions:

• HDAC inhibitors represent a promising class of novel anticancer agents.
• Further research is needed to elucidate the molecular mechanisms, particularly tumor selectivity, of HDAC inhibitors.
• Understanding these mechanisms is crucial for advancing cancer therapy.